New Benefits Give SGLT2 Inhibitors Their Turn to Shine - Frankly Speaking Ep 376
Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-376
Overview: While GLP-1 agents are center stage in the medical and lay press, drugs in the class of sodium-glucose cotransporter 2 inhibitors (SGLT2is) are also quite remarkable at improving a variety of health endpoints. This episode provides an overview of studies supporting the use of SGLT2is to improve patient outcomes.
Episode resource links:
Guest: Susan Feeney, DNP, FNP-BC, NP-C
Music Credit: Richard Onorato
Create your
podcast in
minutes
It is Free